Treatment Outcomes and Toxicities for Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab

被引：0
|
作者：
Pakeerathan, Veenaa [1 ]
Babu, Hari [1 ]
Andelkovic, Vladimir [1 ]
机构：
[1] Princess Alexandra Hosp, Woolloongabba, Qld, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：54 / 55
页数：2
相关论文
共 50 条
  • [41] Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma
    Tsuruoka, Mio
    Inoue, Jun
    Ouchi, Keishi
    Uno, Kaname
    Itami, Hideaki
    Ninomiya, Masashi
    Iwata, Tomoaki
    Sano, Akitoshi
    Sato, Kosuke
    Onuki, Masazumi
    Sawahashi, Satoko
    Koike, Tomoyuki
    Masamune, Atsushi
    INTERNAL MEDICINE, 2023, 62 (10) : 1467 - 1472
  • [42] Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
    Lee, Kyung-Hun
    Lee, Michael S.
    LANCET ONCOLOGY, 2020, 21 (09): : E413 - E413
  • [43] Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies
    Liu, Xiufeng
    Lu, Yi
    Qin, Shukui
    FUTURE ONCOLOGY, 2021, 17 (17) : 2243 - 2256
  • [44] RISK OF BLEEDING IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Kim, Young Seok
    HEPATOLOGY, 2024, 80
  • [45] Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
    Tamaki, Nobuharu
    Tada, Toshifumi
    Kurosaki, Masayuki
    Yasui, Yutaka
    Ochi, Hironori
    Mashiba, Toshie
    Sakamoto, Azusa
    Marusawa, Hiroyuki
    Narita, Ryoichi
    Uchida, Yasushi
    Akahane, Takehiro
    Kondo, Masahiko
    Mori, Nami
    Takaki, Shintaro
    Tsuji, Keiji
    Kobashi, Haruhiko
    Kusakabe, Atsunori
    Furuta, Koichiro
    Arai, Hirotaka
    Nonogi, Michiko
    Ogawa, Chikara
    Sato, Takashi
    Tamada, Takashi
    Nakamura, Shinichiro
    Hasebe, Chitomi
    Tsuchiya, Kaoru
    Izumi, Namiki
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) : 1290 - 1297
  • [46] Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
    Celsa, Ciro
    Cabibbo, Giuseppe
    Fulgenzi, Claudia Angela Maria
    Battaglia, Salvatore
    Enea, Marco
    Scheiner, Bernhard
    D'Alessio, Antonio
    Manfredi, Giulia F.
    Stefanini, Bernardo
    Nishida, Naoshi
    Galle, Peter R.
    Schulze, Kornelius
    Wege, Henning
    Ciccia, Roberta
    Hsu, Wei-Fan
    Vivaldi, Caterina
    Wietharn, Brooke
    Lin, Ryan Po-Ting
    Pirozzi, Angelo
    Pressiani, Tiziana
    Dalbeni, Andrea
    Natola, Leonardo A.
    Auriemma, Alessandra
    Rigamonti, Cristina
    Burlone, Michela
    Parisi, Alessandro
    Huang, Yi-Hsiang
    Lee, Pei-Chang
    Ang, Celina
    Marron, Thomas U.
    Pinter, Matthias
    Cheon, Jaekyung
    Phen, Samuel
    Singal, Amit G.
    Gampa, Anuhya
    Pillai, Anjana
    Roehlen, Natascha
    Thimme, Robert
    Vogel, Arndt
    Soror, Noha
    Ulahannan, Susanna
    Sharma, Rohini
    Sacerdoti, David
    Pirisi, Mario
    Rimassa, Lorenza
    Lin, Chun-Yen
    Saeed, Anwaar
    Masi, Gianluca
    Schoenlein, Martin
    von Felden, Johann
    HEPATOLOGY, 2024,
  • [47] Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Suzuki, Keito
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Matsumoto, Hiroaki
    Yamazaki, Yudai
    Uchihara, Naoki
    Tanaka, Yuki
    Miyamoto, Haruka
    Yamada-Shimizu, Michiko
    Keitoku, Taisei
    Okada, Risa
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Tamaki, Nobuharu
    Nakanishi, Hiroyuki
    Takahashi, Yuka
    Asahina, Yasuhiro
    Okamoto, Ryuichi
    Kurosaki, Masayuki
    Izumi, Namiki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (06) : 1183 - 1189
  • [48] Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Kariyama, Kazuya
    Tani, Joji
    Hirooka, Masashi
    Takaguchi, Koichi
    Atsukawa, Masanori
    Fukunishi, Shinya
    Itobayashi, Ei
    Tsuji, Kunihiko
    Tajiri, Kazuto
    Ochi, Hironori
    Ishikawa, Toru
    Yasuda, Satoshi
    Ogawa, Chikara
    Toyoda, Hidenori
    Hatanaka, Takeshi
    Nishimura, Takashi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Shimada, Noritomo
    Tada, Fujimasa
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Ohama, Hideko
    Morishita, Asahiro
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Kosaka, Hisashi
    Imai, Michitaka
    Naganuma, Atsushi
    Nakamura, Shinichiro
    Koizumi, Yohei
    Matono, Tomomitsu
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    ONCOLOGY, 2023, 101 (04) : 270 - 281
  • [49] Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis
    Song, Young-Gi
    Yeom, Kyeong-Min
    Jung, Eun Ae
    Kim, Sang Gyune
    Kim, Young Seok
    Yoo, Jeong-Ju
    LIVER CANCER, 2024, 13 (06) : 590 - 600
  • [50] Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
    Nobuharu Tamaki
    Toshifumi Tada
    Masayuki Kurosaki
    Yutaka Yasui
    Hironori Ochi
    Toshie Mashiba
    Azusa Sakamoto
    Hiroyuki Marusawa
    Ryoichi Narita
    Yasushi Uchida
    Takehiro Akahane
    Masahiko Kondo
    Nami Mori
    Shintaro Takaki
    Keiji Tsuji
    Haruhiko Kobashi
    Atsunori Kusakabe
    Koichiro Furuta
    Hirotaka Arai
    Michiko Nonogi
    Chikara Ogawa
    Takashi Sato
    Takashi Tamada
    Shinichiro Nakamura
    Chitomi Hasebe
    Kaoru Tsuchiya
    Namiki Izumi
    Investigational New Drugs, 2022, 40 : 1290 - 1297
12345